Navigation Links
Cytopia Commences Second Phase II Study in Brain Cancer
Date:9/4/2008

MELBOURNE, Australia, Sept. 4 /PRNewswire/ -- Cytopia Limited (ASX: CYT) today announced that it is commencing enrolment for its Phase Ib/II study of CYT997, the company's novel vascular-disrupting anticancer agent, in patients with an aggressive form of brain cancer known as glioblastoma multiforme (GBM).

The GBM clinical trial is the first Phase II efficacy study in highly vascular, solid tumor indications for the company and the second in its suite of Phase II studies designed to investigate the anticancer activity of CYT997. Patient recruitment to the study will now commence, following regulatory approval in Australia and the United States.

The clinical study will investigate the activity of CYT997 in combination with two other marketed anticancer agents in approximately 30 patients at a number of clinical centres in Australia and overseas. Dr Jason Lickliter, Director of Oncology at the Frankston Hospital, will be Study Chairman for the program.

GBM is currently treated by surgical resection, and/or radiation and chemotherapy. Despite these treatments, the condition recurs in most patients, leading to a poor prognosis and median survival of less than 12 months. GBM tumors are highly vascular and heavily dependent on their own abnormal blood supply for growth, rendering them potentially susceptible to destruction by an anti-vascular agent such as CYT997.

The following table provides a summary of the key aspects of the Phase II GBM trial.

Name of trial A Phase Ib/II Study of CYT997 in Combination with

Carboplatin and Etoposide in Relapsed Glioblastoma

Multiforme (CCL08001).

Primary endpoints Assess safety and tolerability of escalating doses

of CYT997 given in combination with standard

carboplatin and etoposide therapy (Ph Ib), and

estimation of progression-free survival at six

months using the dose of CYT997 identified in the

Phase Ib component (Ph II).

Secondary endpoints Objective response rate, overall survival, safety

and tolerability, effects on pharmacodynamic

markers of vascular disruption and tumor apoptosis,

and pharmacokinetic analyses.

Blinding status Not blinded.

Product development Drug substance and drug product are manufactured to

status GMP standards.

Treatment method

Route 24 hour intravenous infusion dose (CYT997).

Frequency Day 2 of a 21 day cycle.

Dose-levels Maximum dose of 200 mg/m2 CYT997 dihydrochloride.

Number of trial

subjects Estimated 35 patients.

Subject selection Eligible patients must have glioblastoma multiforme

criteria that has progressed after surgery, radiation

therapy and temozolomide chemotherapy.

Trial location Initial site in Melbourne, Australia.

Expected completion 2Q 2010

Trial standard ICH-GCP

This trial follows the successful conclusion last year of the company's Phase I safety study for intravenous CYT997, in which a prolonged delay in tumor growth was observed in seven of the study's 31 advanced cancer patients.

Significant perturbations in tumor blood flow were also demonstrated, suggesting that CYT997 potently disrupts tumor blood vessels. Findings from this study were recently presented at the American Society of Clinical Oncology Annual Meeting which attracts some 30,000 cancer specialists from around the globe.

Cytopia is also investigating the safety and anti-vascular activity of CYT997 when administered by mouth. Preliminary data from the company's Phase I oral study indicates that the compound is well absorbed after administration in capsule form. This key finding differentiates CYT997 from other vascular disrupting agents currently in development which can only be administered intravenously, limiting their clinical utility.

Enrolment into the company's Phase II study of CYT997 in relapsed multiple myeloma, a disorder of the bone marrow, is also ongoing.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and San Francisco, USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialed in Phase I and Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in early 2009.

Website: http://www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
2. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
3. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
4. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
5. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
6. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
7. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
8. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
9. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
10. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
11. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016  Edwards Lifesciences Corporation (NYSE: EW ... heart disease and critical care monitoring, announced today that ... agreement with Morgan Stanley & Co. LLC to repurchase ... part of the Company,s previously authorized program to repurchase ... --> --> ...
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
(Date:2/4/2016)... Feb. 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ), ... to healthcare systems, today announced results for its fiscal ... --> --> GAAP results: Revenue ... up $5.1 million or 4.1% from the third quarter ... the fourth quarter of 2014. Revenue for the year ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... The event is being held on April 7, 2016 ... Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and ... Parkinson’s disease and is the architect of this informative event to raise awareness and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute ... at the tips of your toes. Foot massage, whether administered by a professional masseuse ... and relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) has ...
(Date:2/5/2016)... ... 2016 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Event at the La Gorce Country Club in Miami Beach on March 15, ...
(Date:2/5/2016)... Grants Pass, OR (PRWEB) , ... February 05, 2016 , ... ... though, with modern technology, such water may be safer than regular municipal or well ... water advocate and radio host Sharon Kleyne, could go a long way toward increasing ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one ... time for this weekend’s Big Game. Take the stress out of your party preparation ... your guests happy at every stage of the game. , “The key to hosting ...
Breaking Medicine News(10 mins):